Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 5,141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: Substance Use, HIV/AIDS, Older Adults, Behavioral Intervention, Infectious Disease
Interventions: Psycho-educational content (5 Minutes), Readiness Assessment (10 minutes), Goal-Setting (5 minutes), Identifying and prioritizing needs (5 minutes), Explanation of Peer Navigator and Session wrap (5 minutes); Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida • Lake City, Florida

Conditions: HIV Infections
Interventions: Antiretroviral Treatment Interruption; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 17 more

Conditions: HIV
Interventions: FP conjugate vaccine (25 mcg), FP conjugate vaccine (200 mcg), Trimer 6931 (100 mcg), Trimer 6931 (200 mcg), Trimer 4571 (200 mcg), Trimer 4571 (100 mcg); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more

Conditions: HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions: r-metHuLeptin, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Human Immunodeficiency Virus
Interventions: Provision of HIV self-test with Commitment and planning prompts, Provision of HIV self-test; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 19 Years and older
Enrollment: 1,479 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unsafe Sex, Risk Reduction
Interventions: PROJECT POWER, Power Health; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: abacavir/lamivudine, abacavir, lamivudine, tenofovir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 30
States / cities: Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 20 more

Conditions: Depression, Stress, Psychological, Self Efficacy, Loneliness, Social Isolation, Health Care Utilization, Dementia, Dementia Alzheimers, Dementia of Alzheimer Type, Dementia, Vascular, Dementia Frontal, Dementia, Lewy Body, Dementia, Mixed, Dementia in Parkinsons Disease, Dementia, HIV, Dementia Frontotemporal, Dementia, Multi-Infarct
Interventions: Building Better Caregivers Workshop, Attention Control; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: Up to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Memphis, Tennessee

Conditions: HIV Infections
Interventions: ACCESS Intervention, Control Group; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV-1-infection
Interventions: VRC07-523LS, PGT121.414.LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 30mg, Placebo, GSK1265744 5mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Vero Beach, Florida + 1 more

Conditions: HIV/AIDS, Stroke
Interventions: Robot Therapy; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Indianapolis, Indiana + 6 more

Conditions: Sexual Transmission of Infection
Interventions: HIV prevention intervention, Diet and Nutrition; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 16 Years to 29 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: HIV Prevention
Interventions: C4 Program, C4 + 3MV Program; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: HEPATITIS C, Virus, Human Immunodeficiency
Interventions: Directly Observed Therapy, Wirelessly Observed Therapy; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Sexually Transmitted Diseases, HIV
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 10 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Paclitaxel; Drug
Lead sponsor: Baker Norton Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV
Interventions: dolutegravir, Triumeq, Truvada; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: HIV Infection, Hepatitis B
Interventions: HEPLISAV-B, ENGERIX-B; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: HIV Infections, Sinusitis
Interventions: Pseudoephedrine hydrochloride, Guaifenesin, Cefuroxime axetil, Beclomethasone dipropionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • The Bronx, New York + 1 more

Conditions: HIV Prevention, Injection Drug Use
Interventions: Mail delivery of at-home self-administered HIV tests; Diagnostic Test
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Feasibility of SBIRT-PN

Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

Plan and Pledge, HIV Self-testing in South Africa

Project Power: An HIV Risk Reduction Intervention for Black Men Who Have Sex With Men and Women (BMSM/W)

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Rural Dementia Caregiver Project

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Robot-Assisted Rehabilitation After HIV-Associated Stroke: Botswana

Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.

HIV Prevention Intervention for Young Transgender Women

Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM

Antiviral Pharmacology and Adherence in Drug Users

Recruiting African American Fathers/ Sons

Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

Dolutegravir in Reservoirs

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Preventing Frequent Sinus Infections in HIV-Infected Patients

Feasibility of Internet-based HIV Prevention Research